Monitoring Eating Across Locations (MEAL) - Timing, Intake, and Mealtime Evaluation (TIME)
Penn State University · NCT07095166
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 6–9 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- November 15, 2025
- Record last updated
- March 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Increased availability of high-energy dense foods has contributed to a pediatric obesity epidemic, with 23% of United States children currently presenting with the disease. How children eat contributes to both overconsumption and greater adiposity. However, it is unclear if laboratory measures of children's eating style generalize to the home environment, where children consume two thirds of their total energy. The study will 1) test if child eating styles observed in the lab generalize to more ecologically valid home environments and 2) identify aspects of home food environment that amplify obesogenic eating behaviors. We will assess laboratory and home eating styles (e.g., bite rate) in 100 prepubertal 6-9-year-old children to constrain variability in energy requirements. Children will be video-recorded while consuming identical study-provided meals at home and in the laboratory (counter-balanced order) in addition to a 'typical' meal at home. To study how adiposity relates to "obesogenic" styles of eating, gold standard dual x-ray absorptiometry will be used.
Being studied: Meal Location
Conditions: Pediatric Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- children must be between the ages of 6-9 years-old
- children are of good health with no learning disabilities (e.g., ADHD, determined by parent report)
- children are not on any medications known to impact body weight, taste, food intake, behavior, or blood flow
- parents report that children like and are willing to eat study foods
Exclusion Criteria
- Children are not within the age requirements (\<6 years old or > 9 years old)
- If children are taking cold or allergy medication, or other medications known to influence cognitive function, taste, appetite, or blood flow.
- If children don't speak English.
- If children are colorblind.
- If children have a learning disability, ADD/ADHD, language delays, autism or other neurological or psychological conditions.
- If children have a pre-existing medical condition such as type I or type II diabetes, rheumatoid arthritis, Cushing's syndrome, Down's syndrome, severe lactose intolerance, Prader-Willi syndrome, HIV, cancer, renal failure, or cerebral palsy.
- If children are allergic to foods or ingredients used in the study.
- child received an X-ray in the previous year (to avoid excess radiation exposure due to the DXA scans performed in the research)
Recruiting US locations
Pennsylvania State University
State College, PA 16801
Site contact: Alaina Pearce, PhD · 3206305713 · azp271@psu.edu
Similar studies in Pennsylvania
All weight loss studies in Pennsylvania →- RecruitingHealthy volunteersPhase 1
Pharmacogenetics of Response to GLP1R Agonists
University of Maryland, Baltimore
- Location
- Lancaster, PA
- Eligibility basics
- Ages 18–89
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Philadelphia, PA + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Beaver, PA + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- West Chester, PA + 43 other US sites
- Eligibility basics
- Ages 18+